trastuzumab-interferon beta R27T

**Trastuzumab-interferon beta R27T** is an investigational HER2-targeted immunocytokine composed of trastuzumab fused through a flexible peptide linker to two copies of the glycoengineered human interferon beta-1a mutein R27T, one on each antibody heavy chain. The R27T interferon component contains an additional N-glycosylation site that was designed to improve stability, solubility, recombinant production, and pharmacokinetics relative to wild-type interferon beta-1a. The trastuzumab domain binds HER2 and preferentially localizes the interferon payload to HER2-expressing tumors, while interferon beta activates type I interferon receptor signaling, producing direct antiproliferative effects and immune-mediated antitumor activity. It has been evaluated preclinically, principally in HER2-positive gastric cancer models, where it showed tumor targeting, direct growth inhibition, enhanced immune-cell cytotoxicity, and superior in vivo antitumor activity versus trastuzumab or IFN-beta-R27T alone. ([frontiersin.org](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.608774/full))

Other names

trastuzumab-R27Ttrastuzumab-R-27Ttrastuzumab-R 27Ttrastuzumab-IFN-beta R27Ttrastuzumab-IFN-beta mutein